Trial intelligence / Profile preview

Chloroprocaine 3% gel vs Oxybuprocaine 0.4% eye drops in pediatric ocular surface anesthesia

2023-504477-21-00Phase 3Withdrawn

Sponsor
Sintetica
Start
Sep 2023
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, single-blind trial in well-being comparing Chloroprocaine 3% eye gel with Oxybuprocaine 0.4% eye drops (2 arms). Primary endpoint: Proportion of patients with successful conjunctival anesthesia in the right eye at 5 minutes after study product administration. Planned start Sep 2023; status: withdrawn.

02

Drugs

chloroprocaineoxybuprocaine
03

Conditions

well-being

Beyond the preview

Go deeper on 2023-504477-21-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-504477-21-00.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call